What is HC Wainwright's Estimate for ABEO Q2 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Abeona Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.39) per share for the quarter, down from their prior estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.37 EPS.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 target price for the company. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Finally, Stifel Nicolaus dropped their target price on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.50.

Abeona Therapeutics Trading Down 2.4%

Shares of NASDAQ:ABEO traded down $0.16 during trading hours on Wednesday, hitting $6.42. 957,198 shares of the company's stock traded hands, compared to its average volume of 619,543. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.32. The business has a fifty day moving average price of $5.29 and a 200-day moving average price of $5.56. The firm has a market capitalization of $328.43 million, a P/E ratio of -2.39 and a beta of 1.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Insider Activity at Abeona Therapeutics

In related news, Director Mark Alvino sold 8,000 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the completion of the sale, the director now owns 92,435 shares in the company, valued at approximately $525,030.80. The trade was a 7.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. The trade was a 1.81% decrease in their position. The disclosure for this sale can be found here. 6.90% of the stock is owned by company insiders.

Institutional Trading of Abeona Therapeutics

A number of large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its holdings in shares of Abeona Therapeutics by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company's stock valued at $954,000 after purchasing an additional 66,422 shares during the period. Newtyn Management LLC raised its stake in Abeona Therapeutics by 26.3% in the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after buying an additional 100,000 shares in the last quarter. Trexquant Investment LP raised its stake in Abeona Therapeutics by 74.1% in the first quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company's stock worth $568,000 after buying an additional 50,758 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after buying an additional 7,155 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Abeona Therapeutics by 64.1% in the first quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company's stock worth $729,000 after buying an additional 59,832 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.